Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis

Cancer

Volumn 121, Issue 7, 2015, Pages 1138-1146

  Shi, Qiuling ^a   Wang, Xin Shelley ^a   Li, Guojun ^a   Shah, Nina D ^a   Orlowski, Robert Z ^a   Williams, Loretta A ^a   Mendoza, Tito R ^a   Cleeland, Charles S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

inflammatory gene; MD Anderson Symptom Inventory (MDASI); multiple myeloma; racial ethnic variation; SNP; symptom

Indexed keywords

ADENINE; CYTOKINE; CYTOSINE; GUANINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; THYMINE; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; DNA; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

1BETA GENE; ADULT; AGED; ALLELE; ARTICLE; BLACK PERSON; BONE PAIN; CANCER DIAGNOSIS; CANCER PATIENT; CAUCASIAN; CLINICAL ASSESSMENT TOOL; CLUSTER ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE GENE; DISEASE SEVERITY; DNA DETERMINATION; ETHNICITY; FATIGUE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC REGULATION; GENOTYPE; HIGH RISK PATIENT; HISPANIC; HUMAN; IL10 GENE; INTERLEUKIN 6 GENE; MAJOR CLINICAL STUDY; MALE; MD ANDERSON SYMPTOM INVENTORY MULTIPLE MYELOMA MODULE; MULTIPLE MYELOMA; ORAL BIOPSY; PAIN; PARESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RACE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; TUMOR NECROSIS FACTOR ALPHA GENE; ANCESTRY GROUP; COMPLICATION; ETHNIC GROUP; ETHNOLOGY; FOLLOW UP; GENETICS; INFLAMMATION; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CONTINENTAL POPULATION GROUPS; CROSS-SECTIONAL STUDIES; DNA, NEOPLASM; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925444546     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29154     Document Type: Article

References (44)

1. National Cancer Institute. Surveillance, Epidemiology, and End Results program: turning cancer data into discovery. http://seer.cancer.gov/. Accessed May 2, 2014.
2. Zou Y, Lin M, Sheng Z, Niu S,. Bortezomib and lenalidomide as front-line therapy for multiple myeloma. Leuk Lymphoma. 2014; 55: 2024-2031.
3. Sonneveld P, Goldschmidt H, Rosinol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013; 31: 3279-3287.
4. Eshaghian S, Berenson JR,. Multiple myeloma: improved outcomes with new therapeutic approaches. Curr Opin Support Palliat Care. 2012; 6: 330-336.
5. Larocca A, Palumbo A,. Evolving paradigms in the treatment of newly diagnosed multiple myeloma. J Natl Compr Canc Netw. 2011; 9: 1186-1196.
6. Sonneveld P, Verelst SG, Lewis P, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013; 27: 1959-1969.
7. Sprangers MA, Sloan JA, Barsevick A, et al. Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Qual Life Res. 2010; 19: 1395-1403.
8. Sprangers MA, Thong MS, Bartels M, et al. Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: an update. Qual Life Res. 2014; 23: 1997-2013.
9. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003; 97: 2919-2925.
10. Maier SF, Watkins LR,. Immune-to-central nervous system communication and its role in modulating pain and cognition: implications for cancer and cancer treatment. Brain Behav Immun. 2003; 17 (suppl 1): S125-S131.
11. Wang XS, Shi Q, Williams LA, et al. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer. 2008; 113: 2102-2109.
12. Wang XS, Shi Q, Shah N, et al. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res. 2014; 20: 1366-1374.
13. Wang XS, Shi Q, Williams LA, et al. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun. 2010; 24: 968-974.
14. Wang XS, Williams LA, Krishnan S, et al. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun. 2012; 26: 699-705.
15. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998; 102: 1369-1376.
16. di Giovine FS, Takhsh E, Blakemore AI, Duff GW,. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet. 1992; 1: 450.
17. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW,. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997; 94: 3195-3199.
18. Banu C, Moise A, Arion CV, Coriu D, Tanase A, Constantinescu I,. Cytokine gene polymorphisms support diagnostic monitoring of Romanian multiple myeloma patients. J Med Life. 2011; 4: 264-268.
19. Vangsted AJ, Nielsen KR, Klausen TW, Haukaas E, Tjonneland A, Vogel U,. A functional polymorphism in the promoter region of the IL1B gene is associated with risk of multiple myeloma. Br J Haematol. 2012; 158: 515-518.
20. Bower JE, Ganz PA, Irwin MR, Castellon S, Arevalo J, Cole SW,. Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol. 2013; 31: 1656-1661.
21. Rausch SM, Clark MM, Patten C, et al. Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors. Cancer. 2010; 116: 4103-4113.
22. Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975-2007. http://seer.cancer.gov/csr/1975-2007/. Accessed June 15, 2014.
23. Eskdale J, Keijsers V, Huizinga T, Gallagher G,. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun. 1999; 1: 151-155.
24. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000; 89: 1634-1646.
25. Jones D, Vichaya EG, Wang XS, et al. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol. 2013; 6: 13.
26. Isohelix, Ltd. DNA sampling and purification. http://www.isohelix.com/documentation/. Accessed May 2, 2014.
27. Qiagen. Gentra Puregene blood kit. http://www.qiagen.com/products/catalog/sample-technologies/dna-sample-technologies/genomic-dna/gentra-puregene-blood-kit. Accessed May 2, 2014.
28. Jin L, Sturgis EM, Zhang Y, et al. Association of tumor necrosis factor-alpha promoter variants with risk of HPV-associated oral squamous cell carcinoma. Mol Cancer. 2013; 12: 80.
29. Jin L, Sturgis EM, Cao X, et al. Interleukin-10 promoter variants predict HPV-positive tumors and survival of squamous cell carcinoma of the oropharynx. FASEB J. 2013; 27: 2496-2503.
30. Wang XS, Zhao F, Fisch MJ, et al. Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. Cancer. 2014; 120: 425-432.
31. Norusis MJ. PASW Statistics 18 Statistical Procedures Companion. Upper Saddle River, NJ: Prentice Hall; 2010.
32. Cohen J,. The statistical power of abnormal-social psychological research: a review. J Abnorm Soc Psychol. 1962; 65: 145-153.
33. Ivanova M, Ruiqing J, Kawai S, et al. IL-6 SNP diversity among four ethnic groups as revealed by bead-based liquid array profiling. Int J Immunogenet. 2011; 38: 17-20.
34. Zabaleta J, Schneider BG, Ryckman K, et al. Ethnic differences in cytokine gene polymorphisms: potential implications for cancer development. Cancer Immunol Immunother. 2008; 57: 107-114.
35. Hosmer DW, Lemeshow S,. Assessing the fit of the model. In:, Hosmer DW, Lemeshow S, eds. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons; 2000: 143-202.
36. Boos DD,. Introduction to the bootstrap world. Stat Sci. 2003; 18: 168-174.
37. Austin PC, Tu JV,. Bootstrap methods for developing predictive models. Am Stat. 2004; 58: 131-137.
38. Reinertsen KV, Grenaker Alnaes GI, Landmark-Hoyvik H, et al. Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. Brain Behav Immun. 2011; 25: 1376-1383.
39. Jim HS, Park JY, Permuth-Wey J, et al. Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: preliminary findings. Brain Behav Immun. 2012; 26: 1030-1036.
40. Tosato G, Jones KD,. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood. 1990; 75: 1305-1310.
41. Merriman JD, Aouizerat BE, Cataldo JK, et al. Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast cancer. Cytokine. 2014; 65: 192-201.
42. Camargo MC, Mera R, Correa P, et al. Interleukin-1 β and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1674-1687.
43. Kaya H, Peressini B, Jawed I, et al. Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol. 2012; 95: 64-70.
44. Shi Q, Mendoza TR, Gunn GB, Wang XS, Rosenthal DI, Cleeland CS,. Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Qual Life Res. 2013; 22: 2331-2339.